Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022).

"We have been able to show a correlation between patient survival and a measure of the cumulative potency of PROVENGE; such a correlation between product potency and clinical outcome has not been previously demonstrated with an active immunotherapy," said Mark Frohlich, MD, chief medical officer of Dendreon. "These data provide further evidence that sipuleucel-T is actively engaging the immune system in a clinically meaningful way that prolongs patient survival."

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease. Currently, there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... Mass. and JERUSALEM , ... biopharma company developing octreotide capsules, its lead product for ... a $70 million Series E financing round. Participants in ... Sofinnova Ventures, and an undisclosed blue chip public investment ... Capital, 7 Med Health Ventures, Abingworth and ARCH Venture ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... offering of 5,250,000 shares of its common stock at ... The net proceeds to Tandem from this offering are ... and commissions and other estimated offering expenses payable by ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... , , SILVER SPRING, Md. , Feb. ... approved Xiaflex (collagenase clostridium histolyticum) as the first drug to ... can affect a person,s ability to straighten and properly use ... affects the connective tissue found beneath the skin in the ...
... 2 Vermillion, Inc. (Pink Sheets: VRML) today announced the reappointment ... Company and Eric T. Fung , MD, PhD as Senior Vice ... announced appointment of William C. Wallen , PhD to the Board ... Chair of the Board of Directors. , "Both Dr. Fung and I ...
Cached Medicine Technology:FDA Approves Xiaflex for Debilitating Hand Condition 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 3Vermillion Announces the Reappointment of Officers and Confirmation of Director 4
(Date:3/1/2015)... Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... , which is approved to treat Overactive Bladder (OAB) symptoms, ... and frequency in adults when another type of medication (anticholinergic) ... This is a different treatment option that takes another approach ... , BOTOX® works on the nerves and bladder ...
(Date:3/1/2015)... NY (PRWEB) March 01, 2015 Adults ... seek insurance rates for term or universal policies can ... some of the best life insurance companies for single ... the system at http://quotespros.com/life-insurance.html . , The rate ... search portal are tied to a number of life ...
(Date:3/1/2015)... New York, New York (PRWEB) March 01, 2015 ... Wright Profemur hip lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled ... that the defense must prepare a witness to ... implant played in the development of the Profemur ... Order filed in U.S. District Court, Northern District ...
(Date:3/1/2015)... 2015 The number of transvaginal mesh ... past few weeks in two New Jersey litigations where ... the Firm announces. , A Case List updated ... Bergen County proceeding established for products manufactured by Johnson ... weeks earlier, when 90 fewer cases had been centralized. ...
(Date:3/1/2015)... Atlanta, GA (PRWEB) March 01, 2015 ... of Evelyn King and Carolyn Roddy to the professional ... Director of Compliance, graduated from The Ohio State University-Mortiz ... over 15 years of experience working with several Fortune ... specifically in the area of corporate benefits. Her experiences ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2
... of Public Health, Walter Reed Army Institute of Research, and ... that the risk of multiple sclerosis (MS) increases by many ... implicates EBV as a contributory cause to multiple sclerosis. The ... Annals of Neurology and will appear in a later print ...
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
... new EEG study conducted on college students ... the default mode network, a suggested natural "ground state" ... Meditation technique. This three-month randomized control study is published ... dedicated to the Neuroscience of Meditation and ...
... germs that increased appetite from one mouse to another ... may contribute to obesity and metabolic syndrome, a new ... that the obesity epidemic in the developed world is ... of low-cost, high-calorie foods. However, our results suggest that ...
Cached Medicine News:Health News:Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis 2Health News:Bedbugs, Scabies and Head Lice - Oh My! 2Health News:Bedbugs, Scabies and Head Lice - Oh My! 3Health News:Bedbugs, Scabies and Head Lice - Oh My! 4Health News:Bedbugs, Scabies and Head Lice - Oh My! 5Health News:Bedbugs, Scabies and Head Lice - Oh My! 6Health News:Bedbugs, Scabies and Head Lice - Oh My! 7Health News:Bedbugs, Scabies and Head Lice - Oh My! 8Health News:Bedbugs, Scabies and Head Lice - Oh My! 9Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 2Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 3Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 4Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 5Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 6Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 7Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 8Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 9Health News:The SCOOTER Store Announces Coast-to-Coast Expansion of Local Stores 2Health News:The SCOOTER Store Announces Coast-to-Coast Expansion of Local Stores 3Health News:The SCOOTER Store Announces Coast-to-Coast Expansion of Local Stores 4Health News:Transcendental Meditation activates default mode network, the brain's natural ground state 2Health News:Gut Bacteria May Spur Obesity, Research Suggests 2
... Penile Prosthesis,The AMS DURA ... made of cobalt-chrome alloy ... that gives patients what ... of positioning, cosmetic concealment ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
... leg bags are part of the ... line of leg bags, kits, and ... needs of our customers. These leg ... and constructed of 100% latex-free soft, ...
Medicine Products: